The Latest Cannabis Articles from Streetwise Reports


Aurora Cannabis 'Upside Breakout Looks Imminent'

Contributed Opinion
  ()
Technical analyst Clive Maund charts the cannabis company and explains why he calls it an "immediate strong buy." read more >

COVID-19: A Catalyst for Small-Cap Outperformance

Contributed Opinion
  ()
Steve Palmer, president and chief investment officer of AlphaNorth Asset Management, outlines why he believes Canadian companies on the TSX Venture Index remain good investments in a time of pandemic uncertainty. read more >

Vertically Integrated Hemp/CBD Player Sweet Earth Holdings Debuts on CSE

Contributed Opinion
  ()
With CBD showing some promise against Covid-19 and cannabis stocks rising, Peter Epstein of Epstein Research discusses the market with Sweet Earth Holdings executives. read more >
News Update

Cannabis Cultivator Shifts Focus to Commercializing Technology

News Update
  ()
Sproutly Canada has received capital investment from Infusion Biosciences. read more >

Aurora Cannabis Shares Catch Fire on Positive Q3/20 Financial Results

  ()
Shares of Aurora Cannabis traded 60% higher after the company reported an 18% rise in net revenue, which included a 24% increase in consumer sales versus to the prior quarter. read more >
News Update

Cannabis Beverage and Edibles Supplier Signs Agreements with Manitoba and Saskatchewan

News Update
  ()
Sproutly Canada's subsidiary company Toronto Herbal Remedies has entered into a cannabis supply contract with Manitoba and Saskatchewan provinces to carry the firm's CALIBER brand indoor-grown dried flower products. read more >
News Update

Cannabis Firm Outlines Business Strategies for Custom Formulations

News Update
  ()
The company plans to accelerate the path to greater revenues and profitability. read more >

California Gold: Two U.S. Hemp Revenue Streams Coming Online This Quarter

Contributed Opinion
  ()
Peter Epstein of Epstein Research discusses recent developments at the company. read more >

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

  ()
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. read more >
Showing Results: 1 to 9 of 9

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe